Polen Thomas E Jr sold (to issuer) $3.6M of BDX

Polen Thomas E Jr (Chairman, CEO and President) sold (to issuer) 17,246 shares of BECTON DICKINSON & CO (BDX) at $210.00 ($3.62M total) on 2026-11-05 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Polen Thomas E Jr
Published Nov 9, 2026, 10:44 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 9, 2026, 10:50 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$BDX
Bearish
medium confidence
Mentioned
$BDX
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$BDXBearishLow
01

Why it matters

The insider transaction provides fresh data on insider sentiment; while not large enough to move the stock dramatically, it may influence short‑term trading.

02

Market read

Primary disclosure of an insider sale; modest relevance for traders monitoring insider activity.

03

What to watch

Potential upcoming capital allocation decisions or buyback plans that may offset the sell pressure.

Relevance 5/10Novelty 5/10Timing: after-hours filing

Background

SEC Form 4 filing by Becton Dickinson & Co. CEO Polen Thomas E. Jr. reporting a 10b5‑1 planned sale of shares.

Company-level read

Ticker impact

$BDXBearishMedium confidence
Context

Form 4 shows CEO sold 17,246 shares for $3.62M, reducing his stake to 113,156 shares.

Expected impact

likely downward pressure as market prices in the insider sell

Evidence & confidence

The sale is sizable for an insider but not material to overall float; traders may watch for further insider activity.

Market effects

Minimal impact on the medical devices sector; the sale is company‑specific.

None

Low

Counterpoint

The sale could be a routine liquidity event unrelated to fundamentals.

Key entities

  • Polen Thomas E Jr

    Chairman, CEO and President of Becton Dickinson & Co.

  • Becton Dickinson & Co.

    Medical technology and device manufacturer (ticker BDX).

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$AAPLMed

New Australian Data Shed Even More Light on Tax Avoidance by Big Tech (and Others), Highlight Need for Better Disclosure in the U.S.

The Australian Taxation Office released country-by-country tax reports, revealing that Apple (25% of profits in Singapore) and Visa (62% of profits in Singapore) booked significant profits in low-tax jurisdictions. Becton Dickinson reported $266.2M pretax income in the Cayman Islands with no local employees. The data highlights discrepancies between U.S. and Australian disclosures, raising concerns about tax transparency.

$BDXMedAI 8/10

Becton, Dickinson and Company Q4 Earnings Call Highlights

Becton, Dickinson (BDX) reported Q4 earnings, with revenue growth in Interventional (7.6%) and BioPharma Systems (7%). The company expects Q1 adjusted EPS of $2.32-$2.37, with full-year margins flat. BDX plans to discuss long-term targets on Dec. 10. Free cash flow rose 42% to $2.9B, with $3.6B returned to shareholders. BDX has a $19B U.S. investment agreement, potentially easing future tariffs.

$BDXHighAI 8/10

Becton Dickinson & Co (BDX) (Q4 2026) Earnings Call Highlights: Strong Q4 Beat, $19

Becton Dickinson (BDX) reported strong Q4 2026 results but issued cautious fiscal 2027 guidance, expecting low single-digit revenue growth due to a 200 basis point Alaris headwind. Adjusted operating margins are expected to remain flat, with inflation and investments offsetting productivity gains. The company's Q1 guidance is conservative, impacted by system cutovers and the Alaris comparison. Tariff relief benefits are not included in the guidance due to uncertainty.